$VIVO (Meridian Bioscience, Inc.)

$VIVO {{ '2015-11-18T19:05:31+0000' | timeago}} • Announcement

Clinical diagnostic kits maker $VIVO said it has received clearance from FDA for new illumigene Pertussis molecular amplification test claims, which reduces the effect of inhibitors in biologic samples. This test expands Company's customer base by including specimens collected by ESwab, a liquid-based collection and transport system.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$TMO {{ '2017-07-19T12:44:47+0000' | timeago}} • Announcement

$TMO priced an offering of EUR2.6Bil of senior notes. The issuance of the notes is expected to close on or about July 24, 2017. $TMO plans to use all of net proceeds to fund a portion of consideration payable for its acquisition of Patheon, including the repayment of debt of Patheon to be assumed by $TMO, which is estimated to be about $7.2Bil.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$JNJ {{ '2017-07-18T11:59:48+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphics: Q2 2017 highlights

$JNJ {{ '2017-07-18T11:26:59+0000' | timeago}} • Announcement

Medical Devices segment was the top performer for $JNJ in 2Q17, with a growth of 4.9%. While Consumer segment added to this with a 1.7% growth, Pharmaceutical segment edged down 0.2%.

$JNJ {{ '2017-07-18T11:19:55+0000' | timeago}} • Announcement

$JNJ CEO Alex Gorsky said, "Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA as well as the submission and approval of several key line extensions. We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year."

$JNJ {{ '2017-07-18T11:14:25+0000' | timeago}} • Announcement

$JNJ, which recently acquired Actelion Ltd for $30Bil, raised its sales guidance for FY17 to $75.8-76.1Bil. Additionally, the New Brunswick, NJ - based company raised its adjusted earnings guidance for the same period to $7.12-7.22 per share.

$JNJ {{ '2017-07-18T11:08:14+0000' | timeago}} • Announcement

Pharmaceutical giant $JNJ reported growth in sales and adjusted EPS in 2Q17. While sales increased 2% to $18.8Bil riding on International sales growth of 2.3%, adjusted EPS stood at $1.83, representing an increase of 3.1%. On a GAAP basis, net earnings were down to $3.8Bil, or $1.40 per share, compared to $4Bil, or $1.43 per share, a year ago.

$JNJ {{ '2017-07-17T15:58:16+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 3Q17 of $0.84 per share on its common stock. The dividend is payable on September 12, 2017 to shareholders of record as on August 29, 2017. The ex-dividend date is August 25, 2017.

$NEOG {{ '2017-07-17T13:08:38+0000' | timeago}} • Announcement

$NEOG appointed John Adent as CEO, effective immediately. James Herbert, the company’s founder and former CEO, will remain as executive chairman and work closely with Adent in the transition of responsibilities.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

Recent Transcripts

NEOG (Neogen Corp.)
Tuesday, July 18 2017 - 3:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
ICCC (ImmuCell Corp.)
Thursday, May 11 2017 - 8:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, May 10 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
BIO.B (Bio-Rad Laboratories, Inc.)
Thursday, May 4 2017 - 9:00pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, May 2 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
TRIB (Trinity Biotech plc)
Thursday, April 27 2017 - 3:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, April 26 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, April 25 2017 - 9:00pm

AlphaGraphics you may like